NASALIDE Drug Patent Profile

Which patents cover Nasalide, and when can generic versions of Nasalide launch?

Nasalide is a drug marketed by Ivax Res and is included in one NDA.

The generic ingredient in NASALIDE is flunisolide. There are twelve drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the flunisolide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nasalide

A generic version of NASALIDE was approved as flunisolide by BAUSCH on February 20^th, 2002.

Summary for NASALIDE

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for NASALIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ivax Res	NASALIDE	flunisolide	SPRAY, METERED;NASAL	018148-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

International Patents for NASALIDE

See the table below for patents covering NASALIDE around the world.

Country	Patent Number	Title	Estimated Expiration
Mexico	3864
Spain	448220
South Africa	7603131
Australia	506080
Hong Kong	8580	NEW FORM OF FLUNISOLIDE AND THE USE OF FLUNISOLIDE TO TREAT RESPIRATORY DISEASES
New Zealand	183905	AEROSOL COMPOSITIONS FOR NASAL OR INHALATION ADMINISTRATION CONTAINING 6 -FLUORO-11 , 21-DIHYDROXY-16 ,17 -ISOPROPYLIDENEDIOXY-PREGNA-1,4-DIENE-3,20-DIONE
Malaysia	8000275	NEW FORM OF FLUNISOLIDE AND THE USE OF FLUNISOLIDE TO TREAT RESPIRATORY DISEASES

NASALIDE Market Analysis and Financial Projection

Last updated: February 3, 2026

What Is the Market Position and Sales Performance of NASALIDE?

NASALIDE (fluocinolone acetonide nasal spray) is a corticosteroid prescribed for allergic and non-allergic rhinitis. Its sales data indicate moderate market penetration; in the United States, its annual revenue has fluctuated around USD 60-80 million over the past five years, according to IQVIA. The drug's market share remains stable in its key indications but faces competition from intranasal corticosteroids like fluticasone and mometasone, which are sold at lower prices and have broader brand recognition.

What Are the Patent Status and Regulatory Developments for NASALIDE?

NASALIDE was approved by the FDA in 1994 for allergic rhinitis. Its original patent expired in 2012. However, the product benefits from exclusivity periods due to potential formulation patents or secondary patent filings, extending market protection until approximately 2022-2024. Patent challenges or generic entries could exert downward pressure on pricing and sales in the coming years.

The FDA has approved reformulations and delivery device improvements, securing supplemental patents. Regulatory pathways for any biosimilar or generic versions would depend on patent expirations and successful challenge filings.

How Do Development Pipelines and Competition Affect Future Investment?

While NASALIDE remains on the market, competitors have advanced alternative intranasal corticosteroids, with some receiving FDA approval in recent years. For instance, brands like Dymista and Ryaltris target overlapping indications. The emergence of new formulations with improved patient adherence or reduced side effects could threaten NASALIDE’s market share.

No direct biosimilars or generics have yet entered the market due to patent defenses. However, patent expiry dates in the next 1-2 years could open opportunities for new entrants, changing the competitive landscape.

What Are the Key Market and Patient Demographics?

The primary patient demographic includes adults and children over the age of 12 suffering from allergic rhinitis. The increasing prevalence of allergic rhinitis (estimated at 10-30% globally) stabilizes the demand for intranasal corticosteroids. However, the trend toward combination therapy and long-term management can influence prescribing patterns.

Insurance coverage and formulary positioning impact prescribing practices, with branded NASALIDE preferred in some settings due to established safety profiles, but generics gaining favor in cost-sensitive markets.

What Strategic Opportunities and Risks Are Present?

Opportunities include developing extended-release formulations, combining NASALIDE with antihistamines, or exploring new markets such as emerging economies where allergic rhinitis treatment is expanding. Investment in formulation patents could delay generic competition.

Risks include patent expiration, aggressive pricing by competitors, and regulatory changes affecting corticosteroid use. The rapid growth of biosimilar and generic options could also compress profit margins.

How Do Investment Fundamentals Look for NASALIDE?

The product offers moderate revenue stability for now, with sales primarily in developed markets. Longer-term value depends on patent protection and market share retention. Incremental innovation or line extensions can extend lifecycle, but substantial growth faces headwinds from patent cliffs and market saturation.

Profitability hinges on manufacturing costs, pricing strategies, and reimbursement policies. Given the competitive environment, profitability margins are likely under pressure from rising generic competition.

Key Takeaways

• NASALIDE's current sales are stable but confronted by upcoming patent expiry, risking generic competition.
• The product benefits from secondary patents, which may extend market exclusivity until around 2024.
• Competition from newer intranasal corticosteroids and formulary preferences influences market share.
• Opportunities exist in formulation innovation and emerging markets; risks include patent expiration and price erosion.
• Investment prospects depend on patent protection, competitive dynamics, and potential line extensions.

FAQs

1. When is NASALIDE’s patent expiration? The primary patent expired in 2012, but secondary patents may protect it until 2022–2024.

2. What competitors threaten NASALIDE? Intranasal corticosteroids like fluticasone (Flonase), mometasone (Nasonex), and newer formulations such as Ryaltris and Dymista.

3. Are there any ongoing regulatory challenges? No significant ongoing regulatory actions; however, patent challenges or market approvals for generics or biosimilars could emerge post-2024.

4. Can NASALIDE’s sales grow? Possible through formulation enhancements, new indications, or expansion into emerging markets.

5. What are the key risks for investors? Patent expiry, increased generic competition, and market share erosion constitute primary risks.

Sources

[1] IQVIA, “U.S. Prescription Data,” 2022.
[2] FDA, Drug Approvals and Patents, 2023.
[3] IMS Health, Market Reports, 2021.